Toronto General Hospital

Toronto General Hospital

Founded: during the War of 1812; renamed York General Hospital in 1829

TGH Beds: 406

UHN Researchers: 650

UHN Staff Physicians: 650

TGRI Staff: 491

TGRI Trainees: 336

 

  • (416) 340-4800
  • www.uhn.ca
  • 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 2C4


 

Doctors


Research focus:

Early detection, rapid assessment, diagnosis and treatment of mesothelioma.

Clinic at-a-glance:

Toronto General Hospital (TGH) is one of four centers that are part of the University Health Network (UHN), the Princess Margaret Cancer Centre is another one. TGH also has numerous outpatient clinics. The UHN system offers the premier lung and mesothelioma cancer program in Canada and is a world leader in the treatment of advanced lung diseases. TGH treats more patients with mesothelioma than any other center in Canada. The state-of the-art Interventional Thoracic Surgery Suite is a hybrid endoscopy/surgical suite providing leading-edge procedures such as diagnostic bronchoscopy, airway stenting, photodynamic therapy, VATS pleuroscopy and management of pleural effusion. It helps fast track patients referred to the mesothelioma program by performing diagnostic and therapeutic procedures in a minimally invasive way.TGH houses the Peter Munk Cardiac Center which is a world-class cardiovascular center for heart and lungs. Also part of the TGH is the Maria H. Bacardi Ambulatory Transplant Centre which meets the health needs of organ transplant recipients. The Sprott Department of Surgery is known for successfully completing the most technically difficult procedures anywhere in the world for some of the most complex cases in the country. The Department of Anesthesia and Pain Management offers high-tech anesthesia to effectively treat critically ill patients. Mesothelioma is a significant focus of the Division of Thoracic Surgery, providing a cutting-edge research facility and infrastructure for the early detection, rapid assessment, diagnosis and treatment of mesothelioma. The Mesothelioma Research Program is led by Dr. Marc de Perrot. The Toronto General Research Institute (TGRI) is the research division of TGH. The scientists bring innovative research findings that they discover into actual practice, making clinical breakthroughs that improve patient treatment and care. Research at TGRI includes cardiology, transplantation, immunology and autoimmunity, infectious diseases, tissue injury, diabetes and regenerative medicine.